Process Of Mutation, Cell Fusion, Or Genetic Modification Patents (Class 435/440)
  • Patent number: 7671185
    Abstract: Disclosed are nucleotide sequences encoding monomeric variants of DsRed fluorescent proteins and methods of use thereof.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: March 2, 2010
    Assignees: The University of Chicago, The University of Washington
    Inventors: Benjamin S. Glick, Brooke Bevis, Daniel E. Strongin, David Baker, Michelle Scalley-Kim
  • Patent number: 7670829
    Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: March 2, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Roberto Spagnoli, Tilman Achstetter, Gilles Cauet, Eric Degryse, Bruno Dumas, Denis Pompon, Jacques Winter
  • Patent number: 7666676
    Abstract: The hedgehog pathway in cerebellar cancer cells was modulated with siRNA specifically targeted to the shh and gli-I genes. Silencing of the two genes in a medullablastoma cell line transfected with the siRNAs caused significant reduction of mRNA specific for the targeted shh and gli-I genes and a loss of protein expression. The disclosed methods and compositions may be useful for treatment of a range of primitive neuroectodermal tumors (PNET) by shutting down or modulating the expression of gene products associated with the hedgehog pathway.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: February 23, 2010
    Assignee: St. Joseph's Children's Hospital
    Inventors: Michael J. P. Lawman, Selena Braccili
  • Patent number: 7666642
    Abstract: Nucleic acid molecules from nematodes encoding fatty acid desaturase polypeptides are described. Fatty acid desaturase-like polypeptide sequences are also provided, as are vectors, host cells, and recombinant methods for production of fatty acid desaturase-like nucleotides and polypeptides. Also described are screening methods for identifying inhibitors and/or activators of fatty acid desaturase-like polypeptides, as well as methods for antibody production.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: February 23, 2010
    Assignee: Divergence, Inc.
    Inventors: Andrew P. Kloek, Deryck J. Williams, Merry B. McLaird, John D. Bradley, Jennifer A. Davila-Aponte, Siqun Xu, Anita M. Frevert
  • Patent number: 7666641
    Abstract: The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: February 23, 2010
    Assignee: Heska Corporation
    Inventors: Nancy Wisnewski, Kevin S. Brandt
  • Patent number: 7662587
    Abstract: Disrupting the expression of endogenous Escherichia host cell genes gcvA and spr provides mutant host cells having increased heterologous peptide production relative to control Escherichia host cells. Recombinant Escherichia host cells are provided as well as methods of using such host cells for heterologous peptide production.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: February 16, 2010
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Qiong Cheng, Kevin Michael Croker, Kristin Ruebling-Jass, Hong Wang
  • Patent number: 7662601
    Abstract: Novel cytosine-, thymine- and uracil-DNA glycosylases, subcellular localization peptides, nucleic acid molecules containing the same, methods of identifying such enzymes and their use in various methods including mutagenesis, cell killing and DNA sequencing and modification, are desired.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: February 16, 2010
    Inventors: Hans E. Krokan, Geir Slupphaug, Bodil Kavli, John A. Tainer, Clifford D. Mol
  • Publication number: 20100034849
    Abstract: This invention relates to bicistronic flavivirus vectors, methods of using such vectors in the prevention and treatment of disease, and methods of making such vectors.
    Type: Application
    Filed: January 31, 2008
    Publication date: February 11, 2010
    Applicant: Sanofi Pasteur Biologics Co.
    Inventors: Simon Delagrave, Nathan Brown, Harold Kleanthous, Farshad Guirakhoo, Alexander Rumyantsev
  • Publication number: 20100037352
    Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.
    Type: Application
    Filed: April 24, 2009
    Publication date: February 11, 2010
    Applicant: CERES, INC.
    Inventors: Nickolai ALEXANDROV, Vyacheslav Brover
  • Publication number: 20100031400
    Abstract: The present invention relates to isolated polypeptides having acetylxylan esterase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: July 31, 2009
    Publication date: February 4, 2010
    Applicant: Novozymes A/S
    Inventors: Michelle Maranta, Kimberly Brown
  • Publication number: 20100031399
    Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: July 29, 2009
    Publication date: February 4, 2010
    Applicant: Novozmes A/S
    Inventors: Michelle Maranta, Kimberly Brown
  • Patent number: 7655775
    Abstract: The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the gram-negative bacterium.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: February 2, 2010
    Assignee: CanBiocin, Inc.
    Inventors: Michael E. Stiles, Liru Wang, Marius Jacobu s van Belkum
  • Patent number: 7655447
    Abstract: The present invention relates to polynucleotide related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: February 2, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Paul O. Sheppard
  • Patent number: 7655466
    Abstract: The invention provides a production process for a high-frequent random mutant of an object exogenous gene, wherein a recombinant expression vector in which a eukaryote promoter, an exogenous DNA sequence, an intron enhancer and 3?HS3/4 enhancer are linked is introduced and expressed in an animal cell.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: February 2, 2010
    Assignees: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Takachika Azuma
  • Publication number: 20100021498
    Abstract: This invention relates to a live mutated strain of S. pneumoniae which is incapable of expressing polysaccharide capsule, while still capable of colonizing the nasopharynx of the subject.
    Type: Application
    Filed: March 28, 2007
    Publication date: January 28, 2010
    Inventor: Jeffrey Weiser
  • Patent number: 7651849
    Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: January 26, 2010
    Inventors: Grace DeSantis, Ellen Chi, Jennifer Ann Chaplin, Aileen Milan, Jay M. Short, David Paul Weiner, Mark Madden, Darcy Madden, legal representative, Mark J. Burk, Dan E. Robertson
  • Publication number: 20100009450
    Abstract: A method for cloning and expressing a target gene by homologous recombination, and more particularly a method for cloning and expressing a target gene by homologous recombination, wherein a host cell transformed with a recombinant vector and a plasmid containing a recombinase system is introduced with a linear DNA fragment comprising a target gene and a sequence having homology to the recombinant vector. Because complicated genetic engineering steps, such as the restriction enzyme treatment and ligation of a vector and a target gene, are not required, the cloning of a gene can be performed without needing a high degree of skill, and enzyme cost can be reduced. The inventive method can be effectively used for the massive, high-speed cloning and protein expression of genes, and the disclosed pRMT-iTGR system can be used as an analytical means for improving high-efficiency recombinase.
    Type: Application
    Filed: September 14, 2009
    Publication date: January 14, 2010
    Inventors: Seung-Goo Lee, Jae-Jun Song, Jeong-Min Lee, Jae-Seok Ha
  • Patent number: 7645599
    Abstract: A method for producing optically active alcohols is provided. Optically active alcohols are useful intermediates in pharmaceutical production. The method of the present invention enables simple and efficient production of optically active alcohols with a high optical purity. According to the production method disclosed, optically active alcohols are produced via asymmetric reduction of 3-quinuclidinone using tropinone reductase-I. For example, the use of tropinone reductase-I derived from plants like Datura stramonium and Hyoscyamus niger allows the production of high optical purity (R)-3-quinuclidinol.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: January 12, 2010
    Assignee: Daicel Chemical Industries, Ltd.
    Inventors: Hiroaki Yamamoto, Momoko Ueda, Ritsuzui Pan, Takeshi Hamatani
  • Publication number: 20100003234
    Abstract: This invention relates to molecular and cellular biology and biochemistry. In one aspect, the invention provides polypeptides having cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or ?-glucosidase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides cellulase activity, e.g., endoglucanase, cellobiohydrolase, mannanase and/or ?-glucosidase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts.
    Type: Application
    Filed: January 13, 2006
    Publication date: January 7, 2010
    Applicant: Verenium Corporation
    Inventors: David Blum, Joslin Gemsch, Mark Dycaico
  • Publication number: 20090324640
    Abstract: Attenuated, neuraminidase deficient influenza virus, and compositions and methods to prepare that virus, are provided.
    Type: Application
    Filed: May 1, 2008
    Publication date: December 31, 2009
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Yoshihiro Kawaoka, Masato Hatta
  • Publication number: 20090325298
    Abstract: Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.
    Type: Application
    Filed: November 15, 2006
    Publication date: December 31, 2009
    Inventor: Douglas S. Kernodle
  • Patent number: 7638326
    Abstract: The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: December 29, 2009
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl June, James Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
  • Patent number: 7638325
    Abstract: The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: December 29, 2009
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl June, James Riley, Marcela Maus, Anna Thomas
  • Patent number: 7638298
    Abstract: A novel plant transposon that induces bud mutation, transposase thereof, and a method for efficiently inducing bud mutation by improvement in the transposition efficiency are provided. A novel transposon having terminal inverted repeat sequences (SEQ ID NO: 1 and SEQ ID NO: 2) shown below has been isolated for the first time from carnation (Dianthus caryophyllus) and the nucleotide sequence thereof has been determined. The transposon has contained a gene encoding the transposase in its sequence. The transposon induces bud mutation when it is inserted into a gene. The transposition frequency is elevated due to environmental stress. TAGAGCTGGCAAA---TTTGCCAGCTCTA (SEQ ID NOS 1 & 2, respectively in order of appearance).
    Type: Grant
    Filed: September 16, 2004
    Date of Patent: December 29, 2009
    Assignee: Kirin Beer Kabushiki Kaisha
    Inventors: Masaki Momose, Naoyuki Umemoto, Hiroshi Okawa
  • Patent number: 7638331
    Abstract: The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked to at least one AIG such that the COX-2 promoter is activated in cells that overexpress COX-2, thereby resulting in transcription and translation of the AIG, which in turn activates apoptosis in the cell. Thus, apoptosis is selectively induced in only those cells capable of overexpressing COX-2.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: December 29, 2009
    Assignee: The Administration of the Tulane Rducation Fund
    Inventors: W. Terrance Godbey, Anthony Atala
  • Patent number: 7638133
    Abstract: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which the third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: December 29, 2009
    Assignee: Department of Medical Sciences Ministry of Public Health of Thailand
    Inventors: Mitsuo Honda, Kazuhiro Matsuo, Masaru Kanekiyo, Duanthanorm Promkhatkaew
  • Publication number: 20090317910
    Abstract: The present invention relates to automated methods of introducing multiple nucleic acid sequences into one or more target cells.
    Type: Application
    Filed: April 21, 2009
    Publication date: December 24, 2009
    Applicant: President and Fellows of Harvard College
    Inventors: George M. Church, Harris H. Wang, Farren J. Isaacs
  • Publication number: 20090311745
    Abstract: The present invention relates to a polynucleotide encoding an enzyme having carboxylesterase [E.C. 3.1.1.
    Type: Application
    Filed: May 3, 2007
    Publication date: December 17, 2009
    Applicant: B.R.A.I.N AG
    Inventors: Klaus Liebeton, Jürgen Eck, Uwe Bornscheuer, Dominique Böttcher, Peter Langer, Esen Bellur
  • Publication number: 20090311194
    Abstract: Methods and compositions for using magnetosomes as cellular contrast agents and markers for magnetic resonance imaging are provided. Certain methods involve synthesizing magnetosomes in a cell as directed by a nucleotide construct comprising an exogenous polynucleotide sequence, wherein the magnetosome serves as a contrast agent or marker for magnetic resonance imaging. Methods of synthesizing and isolating magnetosomes for introduction into immune-matched cells within a tissue or subject for use as a contrast agent or marker for magnetic resonance imaging are also provided. Also provided are methods for stably transfecting cells to express a polypeptide that drives or modulates magnetosome production in the cell, cells produced by such methods and methods for their isolation, transgenic animals comprising at least one eukaryotic cell produced by such methods, and vectors and delivery systems for the transfection of such cells.
    Type: Application
    Filed: April 28, 2006
    Publication date: December 17, 2009
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: Xiaoping Philip Hu, Anthony Wing Sang Chan, Omar Zurkiya
  • Publication number: 20090311787
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Application
    Filed: July 2, 2008
    Publication date: December 17, 2009
    Inventor: Jeffrey C. Miller
  • Publication number: 20090311263
    Abstract: A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.
    Type: Application
    Filed: August 20, 2009
    Publication date: December 17, 2009
    Applicant: Human Genome Sciences, Inc.
    Inventors: Gregg A. Hastings, Craig A. Rosen
  • Publication number: 20090305292
    Abstract: The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 10, 2009
    Applicant: MEDICAL RESEARCH COUNCIL
    Inventors: Philipp Holliger, Farid Ghadessy, Marc d'Abbadie
  • Patent number: 7629310
    Abstract: The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous cell decreases phosphorylation of Erk and Akt proteins inhibiting the PI3-kinase/Akt cell survival pathway and promoting apoptotic cell death. In one aspect, the compositions and methods of the present invention are used to inhibit the malignant transformation of cells by the oncogenes H-Ras, N-Ras, K-Ras, EGFR, or ErbB2, or to inhibit the growth of cancer cells transformed by such oncogenes. The compositions and methods of the present invention may be used to inhibit cancer cell growth, inhibit malignant cell transformation, and modulate oncogenic signaling in vivo or in vitro.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: December 8, 2009
    Assignee: University of South Florida
    Inventor: Said M. Sebti
  • Patent number: 7629170
    Abstract: The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties. Examples of such properties include enhanced recombinogenicity, genome copy number, and capacity for expression and/or secretion of proteins and secondary metabolites.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: December 8, 2009
    Assignee: Maxygen, Inc.
    Inventors: Stephen delCardayre, Matthew B. Tobin, Willem P. C. Stemmer, Jon E. Ness, Jeremy S. Minshull, Phillip A. Patten, Venkiteswatan Mani Subramanian, Linda A. Castle, Claus M. Krebber, Steven H. Bass, Ying-Xin Zhang, Anthony R. Cox, Gjalt W. Huisman, Ling Yuan, Joseph A. Affholter
  • Patent number: 7625550
    Abstract: A enhanced method for observing tumor progression, angiogenesis and/or metastasis in animal models in real time is described. The invention employs a skin flap over the area to be observed that can be opened and closed reversibly. The invention also permits simultaneous observation of more than one tumor by use of multiple colors.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: December 1, 2009
    Assignee: Anticancer, Inc.
    Inventors: Meng Yang, Eugene Baranov, Jin Wei Wang
  • Patent number: 7622287
    Abstract: The present invention relates to a method of designing laccase mutants with increased oxidation potential and/or changed pH optimum and/or altered mediator pathway and/or altered O2/OH?-pathway, which method is based on the hitherto unknown three dimensional structure of laccases, wherein the parent laccase is a Myceliophthora thermophila, Polyporus pinsitus, or Coprinus cinereus laccase.
    Type: Grant
    Filed: December 7, 2000
    Date of Patent: November 24, 2009
    Assignee: Novozymes A/S
    Inventors: Allan Svendsen, Feng Xu
  • Patent number: 7622289
    Abstract: Ornithine ?-aminotransferase (OAT) facilitates microtubule assembly in addition to its aminotransferase activity in mitochondria. An N-terminal proteolysis of the first 17 amino acids of OAT block its transport to the mitochondria. The resultant truncated protein (OATC) forms specific complexes with mitotic spindle promoting proteins such as Eg5 and takes on a Ran-dependent spindle-assembly activity. Methods and compositions for inhibiting mitotic spindle assembly in a cell by specifically inhibiting OAT, and methods for screening for inhibitors of (1) the spindle-assembly function of OAT, (2) the protease that N-truncates OAT, (3) the OAT/RanGTP association and (4) the OAT/Eg5 association are disclosed.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: November 24, 2009
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrick Harran, Xiaodong Wang, Gelin Wang
  • Patent number: 7622112
    Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: November 24, 2009
    Inventors: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer
  • Publication number: 20090286283
    Abstract: Disclosed herein is a method of purifying target proteins from a sample using the specific affinity between a peptide tag and a protease inhibitor. Also disclosed herein is an affinity chromatography medium for purifying proteins in which a support has immobilized thereon a protease inhibitor, and an affinity chromatography column containing the affinity chromatography medium.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 19, 2009
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jaeil LEE, Youngsun LEE
  • Publication number: 20090286291
    Abstract: The present invention relates to the biosynthesis of polyketides and derives from the cloning of nucleic acids encoding a polyketide synthase and other associated proteins involved in the synthesis of the polyketide borrelidin. Materials and Methods including enzyme systems, nucleic acids, vectors and cells are provided for the preparation of polyketides including borrelidin and analogues and derivatives thereof. Novel polyketide molecules are also provided.
    Type: Application
    Filed: June 9, 2009
    Publication date: November 19, 2009
    Inventors: Jose A. Salas, Carmen Mendez, Carlos Olano, Cesar Sanchez, Alfredo F. Brana, Barrie Wilkinson, Christine J. Martin, Steven Moss, Peter F. Leadlay, Marko Oliynyk
  • Publication number: 20090285853
    Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.
    Type: Application
    Filed: July 23, 2009
    Publication date: November 19, 2009
    Applicant: MEDIMMUNE, LLC
    Inventors: Xing Cheng, Hyun Jung Park, Hong Jin
  • Publication number: 20090280567
    Abstract: RNA molecules, including siRNA molecules and related control, trackability and exaequo agents with specific stability modifications are provided. These molecules are particularly advantageous as transfection control reagents. The molecules include first and second 5? terminal sense nucleotides with 2?-O-alkyl groups and a label on the first 5? terminal sense nucleotide, in conjunction with at least one additional 2?-O-alkyl pyrimidine modified sense nucleotide, and either: (i) at least one 2? fluoro modified pyrimidine antisense nucleotide and a phosphorylated first 5? terminal antisense nucleotide; or (ii) a first and second 5? terminal antisense nucleotide with 2?-O-alkyl modifications and at least one additional 2?-O-alkyl pyrimidine modified antisense nucleotide.
    Type: Application
    Filed: June 17, 2009
    Publication date: November 12, 2009
    Applicant: DHARMACON, INC.
    Inventors: Devin Leake, Anastasia Khvorova, Yuriy Fedorov, Michael Owen Delaney, Barbara Robertson, Emily Anderson, Angela Reynolds
  • Publication number: 20090280529
    Abstract: The present invention provides a method for the transfection of filamentous fungal cells, comprising providing a multitude of containers, filling into each container an amount of polymer needed for the transfection, filling the cells to be transfected as well as an aqueous solution of transfection reagent into each of the containers, incubating the resulting mixture, removing the transfection reagent from the incubated mixture; and selecting the cells which have been transformed, characterized in that the total volume of the incubating mixture is less than 1 ml per container. Furthermore, the present invention provides the use of transformed filamentous fungal cells for the production of proteins or metabolites.
    Type: Application
    Filed: June 25, 2007
    Publication date: November 12, 2009
    Inventors: Marco Alexander Van Den Berg, Bianca Elisabeth Maria Gielesen, Adriana Marina Riemens
  • Patent number: 7608445
    Abstract: The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.
    Type: Grant
    Filed: May 15, 2003
    Date of Patent: October 27, 2009
    Assignee: Verenium Corporation
    Inventors: Grace Desantis, Jay M. Short, Mark J. Burk, Kelvin Wong, Robert Farwell, Kelly Chatman
  • Patent number: 7608437
    Abstract: A method of producing coryneform bacteria having an improved amino acid or nucleic acid-productivity comprises the steps of introducing a mutation in a promoter sequence of amino acid- or nucleic acid-biosynthesizing genes on a chromosome of a coryneform bacterium so that it is close to a consensus sequence or introducing a change in the promoter sequence of amino acid- or nucleic acid-biosynthesizing genes on the chromosome of a coryneform bacterium by gene recombination so that it is close to a consensus sequence, obtaining mutants of the coryneform amino acid- or nucleic acid-producing microorganism, culturing the mutants and select a mutant capable of producing the intended amino acid or nucleic acid in a large amount. This method allows one of skill in the art to construct a mutant capable of enriching or controlling the expression of an intended gene without using a plasmid and to promote production of amino acids in a high yield, by the recombination or mutation.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: October 27, 2009
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yoko Asakura, Jun Nakamura, Sohei Kanno, Mikiko Suga, Eiichiro Kimura, Hisao Ito, Kazuhiko Matsui, Tsuyoshi Ohsumi, Tsuyoshi Nakamatsu, Osamu Kurahashi
  • Patent number: 7608435
    Abstract: The invention relates to a microorganism, obtained by treating Corynebacterium ammoniagenes KCCM 10488 producing 5?-Xanthylic acid as parent strain with UV radiation and mutation Derivatives such as N-methyl-N?nitro-N-nitrosoguanidine (NTG), Having a resistance to 5-fluorotryptophan which enhances Biosynthesis of N5-N10-tetrahydrofolate used for transferring Two formyl group during the process of puring biosynthesis, making It possible to accumulate 5?xanthylic acid in culture medium at a high Yield and high concentration rate same period of fermentation.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: October 27, 2009
    Assignee: CJ Cheiljedang Corp.
    Inventors: Young-Hoon Park, Jea-Young Chang, Jin-Nam Lee, Ki-Hoon Oh, Jeong-Hwan Kim, Yoon-Suk Oh, Jae-Ick Sim
  • Publication number: 20090263900
    Abstract: Disclosed herein are linear donor molecules comprising homology arms of 50-750 base pairs (e.g., 50-100 base pairs) flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.
    Type: Application
    Filed: April 13, 2009
    Publication date: October 22, 2009
    Inventors: Russell DeKelver, Philip D. Gregory, Michael C. Holmes, Fyodor Urnov
  • Patent number: 7604969
    Abstract: A mutant glucose dehydrogenase having an improved substrate specificity to glucose, which is a protein comprising the amino acid sequence depicted in SEQ ID NO:3 or an amino acid sequence having the substitution, deletion, insertion or addition of one or more amino acid residues excluding amino acid 365 in the amino acid sequence depicted in SEQ ID NO:3 and having a glucose dehydrogenase activity, the amino acid residue corresponding to amino acid 365 being substituted by other amino acid residue.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: October 20, 2009
    Assignee: Arkray, Inc.
    Inventors: Hideaki Yamaoka, Masashi Tsukada
  • Publication number: 20090253205
    Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
    Type: Application
    Filed: February 26, 2009
    Publication date: October 8, 2009
    Applicant: Battelle Energy Alliance, LLC
    Inventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
  • Publication number: 20090255009
    Abstract: A novel cotton variety, designated as FM 9150F, is disclosed. The invention relates to seeds, plants, plant cells, plant tissue, harvested products and cotton lint as well as to hybrid cotton plants and seeds obtained by repeatedly crossing plants of variety FM 9150F with other plants. The invention also relates to plants and varieties produced by the method of essential derivation from plants of FM 9150F and to plants of FM 9150F reproduced by vegetative methods, including but not limited to tissue culture of regenerable cells or tissue from FM 9150F.
    Type: Application
    Filed: April 8, 2009
    Publication date: October 8, 2009
    Applicants: Cotton Seed International Proprietory Limited, Bayer CropScience AG
    Inventor: Michael SWINDLE